Susan Serrao

April 2023: BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes

News /

Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes living below poverty. NORTH BRUNSWICK, N.J., April 13, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma […]

April 2023: BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes Read More »

Proteomic Analysis Identifies Three Reliable Biomarkers of Intestinal Inflammation in the Stools of Patients With Inflammatory Bowel Disease

Publication /

Vitali R, Palone F, Armuzzi A, Fulci V, Negroni A, Carissimi C, Cucchiara S, Stronati L. Journal of Crohn’s and Colitis. 2023 Jan 27;17(1):92-102. doi: 10.1093/ecco-jcc/jjac110. PMID: 36040453.

Proteomic Analysis Identifies Three Reliable Biomarkers of Intestinal Inflammation in the Stools of Patients With Inflammatory Bowel Disease Read More »

January 2023: BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS

News /

NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human immune regulatory protein, announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for

January 2023: BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS Read More »

January 2023: BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases

News /

Company directs clinical effort of its breakthrough therapy to Acute Respiratory Distress Syndrome, for which there are no currently approved treatments. NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human

January 2023: BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases Read More »

Gelsolin as a Potential Biomarker for Endoscopic Activity and Mucosal Healing in Ulcerative Colitis

Publication /

Maeda K, Nakamura M, Yamamura T, Sawada T, Ishikawa E, Oishi A, Ikegami S, Kakushima N, Furukawa K, Iida T, Mizutani Y, Ishikawa T, Ohno E, Honda T, Ishigami M, Kawashima H. Biomedicines. 2022 Apr 9;10(4):872. doi: 10.3390/biomedicines10040872. PMID: 35453622; PMCID: PMC9029534.

Gelsolin as a Potential Biomarker for Endoscopic Activity and Mucosal Healing in Ulcerative Colitis Read More »

March 2022: BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction

News /

Fund in Europe leads investment to progress commercialization of breakthrough gelsolin therapy to treat inflammatory and infectious diseases. NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the completion of a

March 2022: BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction Read More »

February 2022: BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members

News /

New board members bring a wealth of financial, strategy and global health expertise.   NORTH BRUNSWICK, N.J., February 17, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the appointment of Dr. Kerry Maguire and Kris

February 2022: BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members Read More »